person · Reporting owner

Cunningham, Richard Anthony

Disclosed activity across 3 companies

Tapewire entity: 81022
SEC CIK: 0001624783

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Anebulo Pharmaceuticals, Inc.ANEB · Entity 9617	Director · Chief Executive Officer	April 04, 2025	April 08, 2025
Icagen, Inc.NONE · Entity 155263	Chief Executive Officer	April 29, 2019	May 01, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Anebulo Pharmaceuticals, Inc.

Report date April 04, 2025 · Filed April 08, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2035-04-03	Direct	316,352	Reported balance After 2025-04-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-04-04 · Grant · Acquired 316,352 · Balance 316,352 F1: One-sixteenth (1/16) of the shares subject to the option vested and became exercisable on April 4, 2025, with the remainder scheduled to vest and become exercisable in fifteen (15) equal quarterly installments on each July 15, October 15, January 15, and April 15 thereafter, vesting fully on January 15, 2029, in each case, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: One-sixteenth (1/16) of the shares subject to the option vested and became exercisable on April 4, 2025, with the remainder scheduled to vest and become exercisable in fifteen (15) equal quarterly installments on each July 15, October 15, January 15, and April 15 thereafter, vesting fully on January 15, 2029, in each case, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Icagen, Inc.

Report date April 29, 2019 · Filed May 01, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2029-04-29	Direct	154,616	Reported balance After 2019-04-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-04-29 · Grant · Acquired 154,616 · Balance 154,616 F1: These options vest in full immediately upon the date of the grant.

Filing footnotes · ownership attribution and instrument terms

F1: These options vest in full immediately upon the date of the grant.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

TYME TECHNOLOGIES, INC.

Report date September 16, 2022 · Filed September 16, 2022

Section 16 reporting ended · disclosed 2022-09-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Employee Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2030-11-24	Direct	Reported balance After 2022-09-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-09-16 · Disposition to issuer · Disposed 2,000,000 · Balance 0 F1: This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 87,640 shares of Syros common stock for $23.51 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split").
Employee Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.43 · Expires 2031-06-13	Direct	Reported balance After 2022-09-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-09-16 · Disposition to issuer · Disposed 500,000 · Balance 0 F2: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.
Employee Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2032-04-24	Direct	Reported balance After 2022-09-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-09-16 · Disposition to issuer · Disposed 1,326,000 · Balance 0 F3: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 58,105 shares of Syros common stock for $7.53 per share, after giving effect to the Reverse Split.

Filing footnotes · ownership attribution and instrument terms

F1: This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 87,640 shares of Syros common stock for $23.51 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split").

F2: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.

F3: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 58,105 shares of Syros common stock for $7.53 per share, after giving effect to the Reverse Split.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 04, 2025 Filed Apr 8, 2025 01:41 UTC	Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617	GrantStock Option (right to buy) · Derivative	316,352	$0.00 Strike: $1.02	$0.00	Disclosure SEC source: 0001641172-25-003095 · ownership.xml · derivative · entry 1 Cunningham, Richard Anthony · CIK 0001624783 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,352 Underlying: Common Stock · 316,352 shares Expires 2035-04-03 F1 · derivative.exercise_date: One-sixteenth (1/16) of the shares subject to the option vested and became exercisable on April 4, 2025, with the remainder scheduled to vest and become exercisable in fifteen (15) equal quarterly installments on each July 15, October 15, January 15, and April 15 thereafter, vesting fully on January 15, 2029, in each case, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
December 09, 2024 Filed Dec 10, 2024 14:00 UTC	Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617	GrantStock Option (right to buy) · Derivative	254,433	$0.00 Strike: $1.56	$0.00	Disclosure SEC source: 0001493152-24-049381 · ownership.xml · derivative · entry 1 Cunningham, Richard Anthony · CIK 0001624783 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,433 Underlying: Common Stock · 254,433 shares Expires 2034-12-08 F1 · derivative.exercise_date: The shares subject to the options vest immediately on the date of the grant. Read SEC document
October 06, 2023 Filed Oct 11, 2023 21:25 UTC	Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617	GrantStock Option (right to buy) · Derivative	600,000	$0.00 Strike: $3.03	$0.00	Disclosure SEC source: 0001209191-23-052650 · doc4.xml · derivative · entry 1 Cunningham, Richard Anthony · CIK 0001624783 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2033-10-05 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as follows: ratably in 16 quarterly installments (37,500 per installment) on the first day of each calendar quarter commencing with January 1, 2024, such that option will be full vested on October 1, 2027. Read SEC document
September 16, 2022 Filed Sep 16, 2022 18:00 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	Disposition to issuerEmployee Stock Option - Option to buy · Derivative	1,326,000	Not disclosed Strike: $0.33	Not disclosed	Disclosure SEC source: 0000899243-22-031348 · doc4.xml · derivative · entry 3 Cunningham, Richard Anthony · CIK 0001624783 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,326,000 shares Expires 2032-04-24 F3 · price: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 58,105 shares of Syros common stock for $7.53 per share, after giving effect to the Reverse Split. F3 · derivative.exercise_date: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 58,105 shares of Syros common stock for $7.53 per share, after giving effect to the Reverse Split. Read SEC document
September 16, 2022 Filed Sep 16, 2022 18:00 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	Disposition to issuerEmployee Stock Option - Option to buy · Derivative	500,000	Not disclosed Strike: $1.43	Not disclosed	Disclosure SEC source: 0000899243-22-031348 · doc4.xml · derivative · entry 2 Cunningham, Richard Anthony · CIK 0001624783 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2031-06-13 F2 · price: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split. F2 · derivative.exercise_date: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split. Read SEC document
September 16, 2022 Filed Sep 16, 2022 18:00 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	Disposition to issuerEmployee Stock Option - Option to buy · Derivative	2,000,000	Not disclosed Strike: $1.03	Not disclosed	Disclosure SEC source: 0000899243-22-031348 · doc4.xml · derivative · entry 1 Cunningham, Richard Anthony · CIK 0001624783 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000,000 shares Expires 2030-11-24 F1 · price: This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 87,640 shares of Syros common stock for $23.51 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"). F1 · derivative.exercise_date: This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 87,640 shares of Syros common stock for $23.51 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"). Read SEC document
April 25, 2022 Filed Apr 26, 2022 16:05 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	GrantEmployee Stock Option - Option to buy · Derivative	1,326,000	$0.00 Strike: $0.33	$0.00	Disclosure SEC source: 0000899243-22-015652 · doc4.xml · derivative · entry 1 Cunningham, Richard Anthony · CIK 0001624783 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,326,000 Underlying: Common Stock · 1,326,000 shares Expires 2032-04-25 F1 · derivative.exercise_date: This option vests over a four-year period in equal quarterly installments. Read SEC document
June 14, 2021 Filed Jun 16, 2021 16:24 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	GrantEmployee Stock Option - Option to buy · Derivative	500,000	$0.00 Strike: $1.43	$0.00	Disclosure SEC source: 0000899243-21-024144 · doc4.xml · derivative · entry 1 Cunningham, Richard Anthony · CIK 0001624783 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option vests over a four-year period in equal quarterly installments. Read SEC document
November 25, 2020 Filed Nov 30, 2020 16:10 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	GrantEmployee Stock Option - Option to buy · Derivative	2,000,000	$0.00 Strike: $1.03	$0.00	Disclosure SEC source: 0000899243-20-032299 · doc4.xml · derivative · entry 1 Cunningham, Richard Anthony · CIK 0001624783 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2030-11-24 F1 · derivative.exercise_date: This option vests over a four-year period in equal quarterly installments. Read SEC document
April 29, 2019 Filed May 1, 2019 18:25 UTC	Icagen, Inc. NONE · Entity 155263	GrantStock Option · Derivative	154,616	$0.00 Strike: $3.50	$0.00	Disclosure SEC source: 0001213900-19-007622 · ownership.xml · derivative · entry 1 Cunningham, Richard Anthony · CIK 0001624783 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,616 Underlying: Common Stock · 154,616 shares Expires 2029-04-29 F1 · shares: These options vest in full immediately upon the date of the grant. F1 · derivative.exercise_date: These options vest in full immediately upon the date of the grant. Read SEC document
November 14, 2018 Filed Nov 16, 2018 16:18 UTC	Icagen, Inc. NONE · Entity 155263	GrantStock Option · Derivative	535,000	$0.00 Strike: $3.50	$0.00	Disclosure SEC source: 0001213900-18-016061 · ownership.xml · derivative · entry 1 Cunningham, Richard Anthony · CIK 0001624783 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 535,000 Underlying: Common Stock · 535,000 shares Expires 2028-11-14 F1 · shares: The option vest on pro rata on a monthly basis over three years commencing on November 30, 2018. F1 · derivative.exercise_date: The option vest on pro rata on a monthly basis over three years commencing on November 30, 2018. Read SEC document
December 29, 2017 Filed Jan 2, 2018 17:08 UTC	Icagen, Inc. NONE · Entity 155263	GrantWarrant · Derivative	5,357	$0.02 Strike: $3.50	$107.14	Disclosure SEC source: 0001213900-18-000048 · f4122917cunningham_icagen.xml · derivative · entry 2 Cunningham, Richard Anthony · CIK 0001624783 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,357 Underlying: Common Stock · 5,357 shares Expires 2019-12-31 Read SEC document
December 29, 2017 Filed Jan 2, 2018 17:08 UTC	Icagen, Inc. NONE · Entity 155263	PurchaseCommon Stock, $0.001 par value	21,428	$0.37	$7,928.36	Disclosure SEC source: 0001213900-18-000048 · f4122917cunningham_icagen.xml · nonDerivative · entry 1 Cunningham, Richard Anthony · CIK 0001624783 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,428 Read SEC document
March 15, 2017 Filed Mar 16, 2017 17:01 UTC	Icagen, Inc. NONE · Entity 155263	GrantStock Option · Derivative	20,000	$0.00 Strike: $3.50	$0.00	Disclosure SEC source: 0001213900-17-002484 · f4031517cunningham_icageninc.xml · derivative · entry 1 Cunningham, Richard Anthony · CIK 0001624783 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-03-15 F1 · shares: These options vest pro rata on a monthly basis over a three year period. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over a three year period. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.